Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
David T Yeung(Royal Adelaide Hospital), Timothy P. Hughes(Royal Adelaide Hospital), Nicholas Viiala(Liverpool Hospital), Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Naranie Shanmuganathan(South Australia Pathology), Carolyn Grove(The University of Western Australia), David M. Ross(Flinders Medical Centre), Cecily Forsyth(Gosford Hospital), John Reynolds(The Alfred Hospital), Jake Shortt(The University of Melbourne), Lynette Chee(The Royal Melbourne Hospital), Steven Lane(QIMR Berghofer Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Mannu Walia(St Vincents Institute of Medical Research), Ilona Cunningham(The University of Sydney), Peter Browett(University of Auckland), Andrew A Grigg(The University of Melbourne), Matthew Wright(The University of Western Australia), Robin Filshie(St Vincent's Hospital Melbourne), Alwyn Bernard D'Souza(Wellington Hospital)
Cited by 24
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464